The global HIV vaccine enterprise.
AIDS, which twenty-five years ago no one even knew it existed, has become the most serious infectious disease worldwide. The development of an HIV vaccine is one of the most difficult challenges that modern biomedical science is confronting. To address this challenge, scientists may need to organize themselves in a more intense, targeted, and collaborative effort, such as the one proposed by the Global HIV/AIDS Vaccine Enterprise. The enterprise concept proposes to complement the creativity of individual investigators with a collaborative system that ensures a more effective use of human and financial resources to produce new scientific knowledge. It also implies that the scientific knowledge can be harnessed in a targeted way to develop practical solutions to urgent global health problems, including explicit product development activities. Different modalities of the enterprise concept are being explored for the development of drugs to treat tuberculosis and vaccines to prevent malaria.
Esparza
José
J
Bill and Melinda Gates Foundation, Seattle, WA 98102, USA. Jose.Esparza@gatesfoundation.org
D016915:AIDS Vaccines; D000328:Adult; D035843:Biomedical Research; D002648:Child; D002675:Child, Preschool; D014943:Global Health; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007391:International Cooperation
D016915:AIDS Vaccines